Lv5126
1178 积分 2025-11-28 加入
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
1个月前
已完结
Development of Scalable Synthesis of RAS Inhibitor’s Indole Building Block via Flow Chemistry
2个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 3: Optimization of the Deprotection Reaction and the Crystallization for the Final Step of API Synthesis
2个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 2: Synthesis of the Malonamide Core and the Final Intermediate
2个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 1: Synthesis of the Diol Fragment
2个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 4: Control of Mutagenic Impurities during API Synthesis
2个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
2个月前
已完结
Risk of Formaldehyde Contamination in Amines from Residual Dichloromethane
3个月前
已完结
Chiral Inversion and Hydrolysis of Thalidomide: Mechanisms and Catalysis by Bases and Serum Albumin, and Chiral Stability of Teratogenic Metabolites
3个月前
已完结
Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts
3个月前
已完结
皖公网安备34019202002308
